Multifunctional Nanocarriers for Advanced Therapy and Diagnosis

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Bio-Engineered Materials".

Deadline for manuscript submissions: 31 March 2027 | Viewed by 741

Editor


E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, ND 58108-6050, USA
Interests: design, development, and characterization of polymeric nanocarrier-based formulations for targeted delivery of small molecule drugs; plasmid DNA, siRNA, proteins, and peptides to treat cancer and neurological disorders; stem cell-based therapies for regenerative medicine, immunotherapy, and tumor-targeted delivery of chemotherapeutics; pharmacokinetic, toxicokinetic, and metabolic profiling of small molecule drug candidates and biologics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The advancement of drug-delivery systems has significantly enhanced therapeutic efficacy, minimized adverse effects, and facilitated precision medicine. This Special Issue seeks original research articles, reviews, and communications on recent progress in Multifunctional Nanocarriers for Advanced Therapy and Diagnosis that respond to internal or external stimuli, actively target disease sites, or dynamically adapt to the biological environment.

We particularly encourage contributions addressing any of the following themes:

  • Design, synthesis, and physicochemical characterization of nanocarriers.
  • Functionalization with targeting ligands and biomimetic coatings.
  • Stimuli-responsive behaviors, including responses to pH, redox conditions, enzymes, temperature, light, magnetic fields, ultrasound, mechanical forces, and hybrid triggers.
  • Strategies for overcoming biological barriers, such as achieving circulation stability, evading immune clearance, facilitating extravasation, enhancing tumor penetration, improving intracellular trafficking, and promoting lysosomal escape.
  • Controlled or on-demand drug release profiles, co-delivery of multiple active agents, including small molecules, biologics, and nucleic acids, as well as theranostic nanocarriers.
  • Pre-clinical evaluation, including in vitro, ex vivo, and in vivo biodistribution, pharmacokinetics, safety and efficacy assessments, and mechanistic studies.

Dr. Buddhadev Layek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanocarriers
  • targeted drug delivery
  • stimuli-responsive nanoparticles
  • biological barriers
  • smart delivery systems
  • nanotheranostics
  • functionalized nanoparticles

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1697 KB  
Review
Recent Nanotherapeutic Advancements Against HIV-Associated Neurocognitive Disorders (HAND)
by Riddhi Trivedi, Avinash Gothwal, Buddhadev Layek and Jagdish Singh
Biomolecules 2026, 16(5), 728; https://doi.org/10.3390/biom16050728 - 15 May 2026
Viewed by 442
Abstract
HIV-associated neurocognitive disorders (HAND) arise from HIV infection of the central nervous system, resulting in chronic neuroinflammation and progressive neuronal damage that impair cognitive, motor, and behavioral functions. Clinically, HAND encompasses a spectrum of neurological impairments ranging from asymptomatic neurocognitive impairment to severe [...] Read more.
HIV-associated neurocognitive disorders (HAND) arise from HIV infection of the central nervous system, resulting in chronic neuroinflammation and progressive neuronal damage that impair cognitive, motor, and behavioral functions. Clinically, HAND encompasses a spectrum of neurological impairments ranging from asymptomatic neurocognitive impairment to severe HIV-associated dementia. Despite the widespread use of combination antiretroviral therapy (cART) and significant improvements in the life expectancy of people living with HIV, HAND remains prevalent and continues to pose a major clinical challenge. One of the primary limitations of cART is the limited penetration of many antiretroviral drugs across the blood–brain barrier (BBB), thereby allowing the persistence of viral reservoirs within the CNS and contributing to sustained neuroinflammation and neuronal damage. To address these challenges, novel nanotherapeutic strategies have been developed to enhance the delivery of antiretroviral agents to the brain. These approaches include targeted delivery systems and the co-delivery of therapeutics across the BBB through mechanisms such as receptor-mediated transcytosis and other transport pathways. In this review, we discuss the pathophysiological challenges associated with HAND and recent advances in nanotherapeutic approaches designed to improve treatment efficacy. We also discuss the current state of the art in vitro and in vivo models used to test the efficacy of these advanced therapeutics. Finally, we outline the remaining challenges and future prospects for the development of nanotherapeutics to improve the treatment of HAND. Full article
(This article belongs to the Special Issue Multifunctional Nanocarriers for Advanced Therapy and Diagnosis)
Show Figures

Graphical abstract

Back to TopTop